Compare WKHS & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKHS | PSTV |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3M | 37.2M |
| IPO Year | 2008 | 2016 |
| Metric | WKHS | PSTV |
|---|---|---|
| Price | $2.99 | $5.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $21.00 | ★ $55.00 |
| AVG Volume (30 Days) | ★ 170.7K | 130.2K |
| Earning Date | 05-14-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 86.92 | ★ 87.61 |
| EPS | N/A | ★ N/A |
| Revenue | $763,173.00 | ★ $5,213,000.00 |
| Revenue This Year | $89.23 | $13.20 |
| Revenue Next Year | $28.84 | $261.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $0.13 |
| 52 Week High | $11.80 | $8.00 |
| Indicator | WKHS | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 43.44 | 42.17 |
| Support Level | $2.81 | $0.37 |
| Resistance Level | $4.18 | $6.65 |
| Average True Range (ATR) | 0.37 | 0.47 |
| MACD | -0.08 | -0.14 |
| Stochastic Oscillator | 3.75 | 3.45 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric vehicles, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).